NCT04336241View on ClinicalTrials.gov

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2028

Conditions
Cancer
Interventions
BIOLOGICAL

RP2

Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

BIOLOGICAL

nivolumab

Programmed death receptor (PD-1) blocking antibody

Trial Locations (7)

46010

RECRUITING

Hospital Clinico de Valencia, Valencia

119 08035

RECRUITING

Hospital Universitario d'Hebron, Barcelona

10 28050

RECRUITING

Hospital Universitario HM Sanchinarro, Madrid

CH63 4JY

RECRUITING

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

SW3 6JJ

RECRUITING

The Royal Marsden NHS Foundation Trust, London

OX3 9DU

RECRUITING

Churchill Hospital, Oxford

SM2 5PT

WITHDRAWN

Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

Replimune Inc.

INDUSTRY

NCT04336241 - Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter